No Data
No Data
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLiquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday's after-market session. The market value of their outstanding shares is at $1.1 billion. Adagene (NASDAQ:ADAG) shares moved upward
Atara Biotherapeutics Hold Rating Based on Promising Preclinical Data and Awaited Clinical Trials
Stifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)
Express News | Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases